ER+, adjuvant tamoxifen, early stage
This external validation set was kindly provided by the Guy's Hospital, London, United Kingdom, consisting of 77 patients diagnosed with early stage breast cancer and treated with adjuvant tamoxifen monotherapy. Samples were hybridized using Affymetrix U133PLUS2 Genechips™ according to standard Affymetrix protocols. Gene expression values from the CEL were normalized by use of the standard quantile normalization method in RMA.
Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen.
ER+ , adjuvant tamoxifen monotherapy , early stage breast cancer
--
--
--
--
| Sample ID | series | IMS | IBS | IDS | ICR |
|---|---|---|---|---|---|
| GSM232194 | GUYT2 | Her2 | IBD | WID | ICR3 |
| GSM232195 | GUYT2 | LumA | IBD | WID | ICR2 |
| GSM232196 | GUYT2 | NA | IBE | NA | ICR1 |
| GSM232197 | GUYT2 | LumA | IBD | WID | ICR2 |
| GSM232198 | GUYT2 | LumB | IBE | PID | ICR3 |
All fields are editable except the "Sample ID" column. To edit a cell, click within the cell. To edit a "date" cell, click on the calendar icon. To cancel an edit, press the ESC key.
| Sample ID | Series | IMS | IBS | IDS | ICR | Array Sample ID | Sample Title | DMFS 10Y EVENT | DMFS 10Y TIME | Disease Free Survival Event | Distant Met Free Survival Event | Age At Initial Pathologic Diagnosis | Lymph Node Status | ER Status | PR Status | Histology Differentiation Grade | Tumor Size Cm | Pathology T Stage | Disease Free Survival Days | Distant Met Free Survival Days | Type Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GSM232194 | GUYT2 |
Her2 |
IBD |
WID |
ICR3 |
400002990 |
GUYT2_50261 |
DistantMetastasisFree |
10 |
DiseaseFree |
DistantMetastasisFree |
64 |
LN+ |
ER+ |
PR- |
NA |
4.2 |
T2 |
3850 |
3850 |
tamoxifen |
| GSM232195 | GUYT2 |
LumA |
IBD |
WID |
ICR2 |
400002991 |
GUYT2_50262 |
DistantMetastasisFree |
10 |
DiseaseFree |
DistantMetastasisFree |
73 |
LN+ |
ER+ |
PR+ |
G1 |
3 |
T2 |
3959 |
3959 |
tamoxifen |
| GSM232196 | GUYT2 |
NA |
IBE |
NA |
ICR1 |
400002992 |
GUYT2_50263 |
DistantMetastasisFree |
10 |
DiseaseFree |
DistantMetastasisFree |
66 |
LN- |
ER+ |
PR+ |
G1 |
1.83 |
T1c |
3936 |
3936 |
tamoxifen |
| GSM232197 | GUYT2 |
LumA |
IBD |
WID |
ICR2 |
400002993 |
GUYT2_50264 |
DistantMetastasisFree |
9.89 |
DiseaseFree |
DistantMetastasisFree |
66 |
LN- |
ER+ |
PR- |
G3 |
1.7 |
T1c |
3610 |
3610 |
tamoxifen |
| GSM232198 | GUYT2 |
LumB |
IBE |
PID |
ICR3 |
400002994 |
GUYT2_50265 |
DistantMetastasis |
5.73 |
Recurred/Progressed |
DistantMetastasis |
75 |
LN+ |
ER+ |
PR+ |
G3 |
2.1 |
T2 |
2090 |
2090 |
tamoxifen |
| GSM232199 | GUYT2 |
Basal |
IBE |
FID |
ICR4 |
400002995 |
GUYT2_50266 |
DistantMetastasisFree |
10 |
DiseaseFree |
DistantMetastasisFree |
73 |
LN- |
ER+ |
PR- |
G3 |
1.6 |
T1c |
4100 |
4100 |
tamoxifen |
| GSM232200 | GUYT2 |
Her2 |
IBD |
WID |
ICR4 |
400002996 |
GUYT2_50267 |
DistantMetastasisFree |
10 |
DiseaseFree |
DistantMetastasisFree |
63 |
LN+ |
ER+ |
PR- |
G3 |
2.1 |
T2 |
3992 |
3992 |
tamoxifen |
| GSM232201 | GUYT2 |
LumB |
IBE |
PID |
ICR2 |
400002997 |
GUYT2_50269 |
DistantMetastasisFree |
10 |
DiseaseFree |
DistantMetastasisFree |
71 |
LN+ |
ER+ |
PR+ |
G3 |
3.1 |
T2 |
4040 |
4040 |
tamoxifen |
| GSM232202 | GUYT2 |
LumA |
IBD |
PID |
ICR1 |
400002998 |
GUYT2_50270 |
DistantMetastasisFree |
10 |
DiseaseFree |
DistantMetastasisFree |
72 |
LN+ |
ER+ |
PR+ |
G1 |
1.7 |
T1c |
3679 |
3679 |
tamoxifen |
| GSM232203 | GUYT2 |
LumB |
IBD |
PID |
ICR1 |
400002999 |
GUYT2_50271 |
DistantMetastasisFree |
10 |
DiseaseFree |
DistantMetastasisFree |
72 |
LN+ |
ER+ |
PR+ |
G2 |
2.28 |
T2 |
4124 |
4124 |
tamoxifen |
| GSM232204 | GUYT2 |
Her2 |
IBD |
PID |
ICR2 |
400003000 |
GUYT2_50273 |
DistantMetastasisFree |
10 |
DiseaseFree |
DistantMetastasisFree |
82 |
LN- |
ER+ |
PR- |
NA |
1.5 |
T1c |
3847 |
3847 |
tamoxifen |
| GSM232205 | GUYT2 |
LumA |
IBD |
WID |
ICR2 |
400003001 |
GUYT2_50282 |
DistantMetastasisFree |
10 |
DiseaseFree |
DistantMetastasisFree |
62 |
LN+ |
ER+ |
PR+ |
NA |
1.8 |
T1c |
3885 |
3885 |
tamoxifen |
| GSM232206 | GUYT2 |
LumA |
IBD |
FID |
ICR3 |
400003002 |
GUYT2_50284 |
DistantMetastasisFree |
10 |
DiseaseFree |
DistantMetastasisFree |
58 |
LN- |
ER+ |
PR- |
G2 |
2.3 |
T2 |
3712 |
3712 |
tamoxifen |
| GSM232207 | GUYT2 |
Normal |
IBE |
NA |
ICR4 |
400003003 |
GUYT2_50287 |
DistantMetastasisFree |
10 |
DiseaseFree |
DistantMetastasisFree |
60 |
LN- |
ER+ |
PR+ |
G3 |
2.5 |
T2 |
3651 |
3651 |
tamoxifen |
| GSM232208 | GUYT2 |
LumA |
IBD |
WID |
ICR2 |
400003004 |
GUYT2_50290 |
DistantMetastasisFree |
10 |
DiseaseFree |
DistantMetastasisFree |
49 |
LN+ |
ER+ |
PR+ |
G1 |
1.57 |
T1c |
3867 |
3867 |
tamoxifen |
| GSM232209 | GUYT2 |
Normal |
IBE |
NA |
ICR3 |
400003005 |
GUYT2_50291 |
DistantMetastasisFree |
10 |
DiseaseFree |
DistantMetastasisFree |
59 |
LN- |
ER+ |
PR+ |
G1 |
1.38 |
T1c |
3839 |
3839 |
tamoxifen |
| GSM232210 | GUYT2 |
Basal |
IBE |
WID |
ICR3 |
400003006 |
GUYT2_50293 |
DistantMetastasisFree |
8.56 |
DiseaseFree |
DistantMetastasisFree |
51 |
LN- |
ER+ |
PR+ |
G3 |
2.3 |
T2 |
3124 |
3124 |
tamoxifen |
| GSM232211 | GUYT2 |
LumA |
IBD |
PID |
ICR3 |
400003007 |
GUYT2_50294 |
DistantMetastasis |
6.62 |
Recurred/Progressed |
DistantMetastasis |
55 |
LN+ |
ER+ |
PR+ |
G2 |
2.9 |
T2 |
2417 |
2417 |
tamoxifen |
| GSM232212 | GUYT2 |
Basal |
IBE |
WID |
ICR3 |
400003008 |
GUYT2_50296 |
DistantMetastasisFree |
9.12 |
DiseaseFree |
DistantMetastasisFree |
76 |
LN- |
ER+ |
PR+ |
G3 |
3 |
T2 |
3329 |
3329 |
tamoxifen |
| GSM232213 | GUYT2 |
Normal |
IBE |
NA |
ICR1 |
400003009 |
GUYT2_50298 |
DistantMetastasisFree |
10 |
DiseaseFree |
DistantMetastasisFree |
49 |
LN- |
ER+ |
PR+ |
G1 |
1.08 |
T1c |
3664 |
3664 |
tamoxifen |
| GSM232214 | GUYT2 |
LumB |
IBD |
PID |
ICR3 |
400003010 |
GUYT2_50299 |
DistantMetastasisFree |
7.23 |
DiseaseFree |
DistantMetastasisFree |
69 |
LN- |
ER+ |
PR+ |
G2 |
2.6 |
T2 |
2639 |
2639 |
tamoxifen |
| GSM232215 | GUYT2 |
Her2 |
IBD |
WID |
ICR3 |
400003011 |
GUYT2_50300 |
DistantMetastasisFree |
10 |
DiseaseFree |
DistantMetastasisFree |
74 |
LN- |
ER+ |
PR- |
NA |
2.5 |
T2 |
3720 |
3720 |
tamoxifen |
| GSM232216 | GUYT2 |
Normal |
IBE |
NA |
ICR4 |
400003012 |
GUYT2_50301 |
DistantMetastasisFree |
9.01 |
DiseaseFree |
DistantMetastasisFree |
42 |
LN- |
ER+ |
PR+ |
G2 |
1.97 |
T1c |
3287 |
3287 |
tamoxifen |
| GSM232217 | GUYT2 |
Her2 |
IBE |
PID |
ICR2 |
400003013 |
GUYT2_50302 |
DistantMetastasisFree |
10 |
DiseaseFree |
DistantMetastasisFree |
62 |
LN- |
ER+ |
PR- |
G3 |
1.8 |
T1c |
3693 |
3693 |
tamoxifen |
| GSM232218 | GUYT2 |
Normal |
IBE |
NA |
ICR2 |
400003014 |
GUYT2_50305 |
DistantMetastasisFree |
9.47 |
DiseaseFree |
DistantMetastasisFree |
51 |
LN+ |
ER+ |
PR+ |
G1 |
2.6 |
T2 |
3456 |
3456 |
tamoxifen |
| GSM232219 | GUYT2 |
LumA |
IBD |
PID |
ICR2 |
400003015 |
GUYT2_50307 |
DistantMetastasisFree |
8.2 |
DiseaseFree |
DistantMetastasisFree |
52 |
LN+ |
ER+ |
PR+ |
G2 |
2 |
T1c |
2994 |
2994 |
tamoxifen |
| GSM232220 | GUYT2 |
LumB |
IBE |
WID |
ICR4 |
400003016 |
GUYT2_50308 |
DistantMetastasisFree |
8.43 |
DiseaseFree |
DistantMetastasisFree |
59 |
LN- |
ER+ |
PR+ |
G3 |
2.25 |
T2 |
3077 |
3077 |
tamoxifen |
| GSM232221 | GUYT2 |
LumB |
IBE |
PID |
ICR1 |
400003017 |
GUYT2_50313 |
DistantMetastasis |
7.39 |
Recurred/Progressed |
DistantMetastasis |
58 |
LN+ |
ER+ |
PR- |
G3 |
6 |
T3/T4 |
1615 |
2696 |
tamoxifen |
| GSM232222 | GUYT2 |
Her2 |
IBD |
FID |
ICR3 |
400003018 |
GUYT2_50316 |
DistantMetastasis |
3.66 |
Recurred/Progressed |
DistantMetastasis |
65 |
LN+ |
ER+ |
PR- |
G3 |
2.1 |
T2 |
1276 |
1337 |
tamoxifen |
| GSM232223 | GUYT2 |
Her2 |
IBD |
FID |
ICR3 |
400003019 |
GUYT2_50317 |
DistantMetastasisFree |
10 |
DiseaseFree |
DistantMetastasisFree |
50 |
LN+ |
ER+ |
PR+ |
G2 |
2.85 |
T2 |
3900 |
3900 |
tamoxifen |
| GSM232224 | GUYT2 |
Basal |
IBE |
FID |
ICR3 |
400003020 |
GUYT2_50318 |
DistantMetastasisFree |
9.12 |
Recurred/Progressed |
DistantMetastasisFree |
60 |
LN+ |
ER+ |
PR+ |
G3 |
2 |
T1c |
210 |
3330 |
tamoxifen |
| GSM232225 | GUYT2 |
LumB |
IBE |
PID |
ICR1 |
400003021 |
GUYT2_50319 |
DistantMetastasisFree |
9.64 |
DiseaseFree |
DistantMetastasisFree |
68 |
LN- |
ER+ |
PR+ |
G3 |
2.2 |
T2 |
3518 |
3518 |
tamoxifen |
| GSM232226 | GUYT2 |
Normal |
IBE |
NA |
ICR2 |
400003022 |
GUYT2_50320 |
DistantMetastasisFree |
8.41 |
DiseaseFree |
DistantMetastasisFree |
59 |
LN- |
ER+ |
PR- |
NA |
2.4 |
T2 |
3068 |
3068 |
tamoxifen |
| GSM232227 | GUYT2 |
Her2 |
IBE |
FID |
ICR4 |
400003023 |
GUYT2_50321 |
DistantMetastasisFree |
8.92 |
DiseaseFree |
DistantMetastasisFree |
61 |
LN- |
ER+ |
PR+ |
G3 |
3 |
T2 |
3257 |
3257 |
tamoxifen |
| GSM232228 | GUYT2 |
Her2 |
IBE |
PID |
ICR3 |
400003024 |
GUYT2_50322 |
DistantMetastasisFree |
6.87 |
DiseaseFree |
DistantMetastasisFree |
68 |
LN+ |
ER+ |
PR+ |
G3 |
2.85 |
T2 |
2507 |
2507 |
tamoxifen |
| GSM232229 | GUYT2 |
LumB |
IBD |
PID |
ICR3 |
400003025 |
GUYT2_50326 |
DistantMetastasisFree |
9.27 |
DiseaseFree |
DistantMetastasisFree |
64 |
LN- |
ER+ |
PR- |
NA |
2.1 |
T2 |
3383 |
3383 |
tamoxifen |
| GSM232230 | GUYT2 |
LumA |
IBD |
PID |
ICR2 |
400003026 |
GUYT2_50327 |
DistantMetastasisFree |
8.47 |
DiseaseFree |
DistantMetastasisFree |
75 |
LN+ |
ER+ |
PR- |
G1 |
2.8 |
T2 |
3091 |
3091 |
tamoxifen |
| GSM232231 | GUYT2 |
LumB |
IBD |
FID |
ICR4 |
400003027 |
GUYT2_50328 |
DistantMetastasis |
2.11 |
Recurred/Progressed |
DistantMetastasis |
77 |
LN+ |
ER+ |
PR+ |
NA |
4 |
T2 |
758 |
771 |
tamoxifen |
| GSM232232 | GUYT2 |
Normal |
IBE |
NA |
ICR2 |
400003028 |
GUYT2_50330 |
DistantMetastasisFree |
7.85 |
DiseaseFree |
DistantMetastasisFree |
52 |
LN- |
ER+ |
PR+ |
NA |
1.9 |
T1c |
2865 |
2865 |
tamoxifen |
| GSM232233 | GUYT2 |
Normal |
IBE |
NA |
ICR2 |
400003029 |
GUYT2_50333 |
DistantMetastasisFree |
9.16 |
DiseaseFree |
DistantMetastasisFree |
74 |
LN- |
ER+ |
PR+ |
NA |
2 |
T1c |
3345 |
3345 |
tamoxifen |
| GSM232234 | GUYT2 |
Normal |
IBE |
NA |
ICR1 |
400003030 |
GUYT2_50335 |
DistantMetastasisFree |
7.75 |
DiseaseFree |
DistantMetastasisFree |
60 |
LN- |
ER+ |
PR+ |
G2 |
1.3 |
T1c |
2829 |
2829 |
tamoxifen |
| GSM232235 | GUYT2 |
LumA |
IBD |
PID |
ICR1 |
400003031 |
GUYT2_50336 |
DistantMetastasisFree |
8.33 |
DiseaseFree |
DistantMetastasisFree |
63 |
LN+ |
ER+ |
PR+ |
NA |
5 |
T2 |
3040 |
3040 |
tamoxifen |
| GSM232236 | GUYT2 |
Her2 |
IBE |
PID |
ICR1 |
400003032 |
GUYT2_50337 |
DistantMetastasis |
1.28 |
Recurred/Progressed |
DistantMetastasis |
70 |
LN- |
ER+ |
PR- |
G3 |
4 |
T2 |
468 |
468 |
tamoxifen |
| GSM232237 | GUYT2 |
Normal |
IBE |
NA |
ICR1 |
400003033 |
GUYT2_50338 |
DistantMetastasisFree |
8.53 |
DiseaseFree |
DistantMetastasisFree |
47 |
LN- |
ER+ |
PR+ |
NA |
1.6 |
T1c |
3113 |
3113 |
tamoxifen |
| GSM232238 | GUYT2 |
LumA |
IBD |
WID |
ICR3 |
400003034 |
GUYT2_50339 |
DistantMetastasisFree |
7.61 |
Recurred/Progressed |
DistantMetastasisFree |
75 |
LN- |
ER+ |
PR+ |
G2 |
3 |
T2 |
2779 |
2779 |
tamoxifen |
| GSM232239 | GUYT2 |
LumA |
IBD |
WID |
ICR2 |
400003035 |
GUYT2_50341 |
DistantMetastasisFree |
8.85 |
DiseaseFree |
DistantMetastasisFree |
69 |
LN- |
ER+ |
PR+ |
G2 |
1.8 |
T1c |
3232 |
3232 |
tamoxifen |
| GSM232240 | GUYT2 |
Basal |
IBE |
PID |
ICR2 |
400003036 |
GUYT2_50344 |
DistantMetastasisFree |
8.96 |
DiseaseFree |
DistantMetastasisFree |
58 |
LN+ |
ER+ |
PR- |
G3 |
2.1 |
T2 |
3270 |
3270 |
tamoxifen |
| GSM232241 | GUYT2 |
LumA |
IBD |
PID |
ICR1 |
400003037 |
GUYT2_50345 |
DistantMetastasisFree |
7.23 |
DiseaseFree |
DistantMetastasisFree |
75 |
LN- |
ER+ |
PR+ |
G2 |
4 |
T2 |
2639 |
2639 |
tamoxifen |
| GSM232242 | GUYT2 |
Normal |
IBE |
NA |
ICR3 |
400003038 |
GUYT2_50349 |
DistantMetastasisFree |
8.3 |
DiseaseFree |
DistantMetastasisFree |
56 |
LN- |
ER+ |
PR+ |
G2 |
2 |
T1c |
3029 |
3029 |
tamoxifen |
| GSM232243 | GUYT2 |
Normal |
IBE |
NA |
ICR2 |
400003039 |
GUYT2_50353 |
DistantMetastasisFree |
5.43 |
DiseaseFree |
DistantMetastasisFree |
77 |
LN- |
ER+ |
PR+ |
NA |
5 |
T2 |
1982 |
1982 |
tamoxifen |
| GSM232244 | GUYT2 |
LumB |
IBE |
WID |
ICR3 |
400003040 |
GUYT2_50354 |
DistantMetastasisFree |
8.41 |
DiseaseFree |
DistantMetastasisFree |
59 |
LN- |
ER+ |
PR+ |
G3 |
1.6 |
T1c |
3068 |
3068 |
tamoxifen |
| GSM232245 | GUYT2 |
NA |
IBE |
NA |
ICR1 |
400003041 |
GUYT2_50356 |
DistantMetastasisFree |
8.19 |
DiseaseFree |
DistantMetastasisFree |
65 |
LN- |
ER+ |
PR- |
G3 |
2.3 |
T2 |
2991 |
2991 |
tamoxifen |
| GSM232246 | GUYT2 |
Her2 |
IBE |
PID |
ICR1 |
400003042 |
GUYT2_50357 |
DistantMetastasisFree |
8.3 |
DiseaseFree |
DistantMetastasisFree |
67 |
LN+ |
ER+ |
PR+ |
NA |
1.9 |
T1c |
3028 |
3028 |
tamoxifen |
| GSM232247 | GUYT2 |
Normal |
IBE |
NA |
ICR2 |
400003043 |
GUYT2_50361 |
DistantMetastasisFree |
7.63 |
DiseaseFree |
DistantMetastasisFree |
65 |
LN- |
ER+ |
PR+ |
G1 |
1.8 |
T1c |
2785 |
2785 |
tamoxifen |
| GSM232248 | GUYT2 |
Basal |
IBE |
FID |
ICR4 |
400003044 |
GUYT2_50362 |
DistantMetastasisFree |
8.07 |
DiseaseFree |
DistantMetastasisFree |
50 |
LN- |
ER+ |
PR+ |
G2 |
1.2 |
T1c |
2946 |
2946 |
tamoxifen |
| GSM232249 | GUYT2 |
Normal |
IBE |
NA |
ICR1 |
400003045 |
GUYT2_50366 |
DistantMetastasisFree |
7.12 |
DiseaseFree |
DistantMetastasisFree |
73 |
LN+ |
ER+ |
PR+ |
NA |
2 |
T1c |
2599 |
2599 |
tamoxifen |
| GSM232250 | GUYT2 |
LumA |
IBD |
PID |
ICR1 |
400003046 |
GUYT2_50368 |
DistantMetastasisFree |
7.41 |
DiseaseFree |
DistantMetastasisFree |
70 |
LN+ |
ER+ |
PR+ |
G3 |
2.8 |
T2 |
2704 |
2704 |
tamoxifen |
| GSM232251 | GUYT2 |
Normal |
IBE |
NA |
ICR1 |
400003047 |
GUYT2_50369 |
DistantMetastasisFree |
7.1 |
DiseaseFree |
DistantMetastasisFree |
52 |
LN- |
ER+ |
PR+ |
NA |
1.07 |
T1c |
2593 |
2593 |
tamoxifen |
| GSM232252 | GUYT2 |
Her2 |
IBD |
WID |
ICR3 |
400003048 |
GUYT2_50373 |
DistantMetastasisFree |
3.08 |
Recurred/Progressed |
DistantMetastasisFree |
80 |
LN+ |
ER+ |
PR+ |
G1 |
2.9 |
T2 |
1124 |
1124 |
tamoxifen |
| GSM232253 | GUYT2 |
LumB |
IBD |
WID |
ICR2 |
400003049 |
GUYT2_50374 |
DistantMetastasisFree |
7.92 |
DiseaseFree |
DistantMetastasisFree |
80 |
LN+ |
ER+ |
PR+ |
G2 |
3.8 |
T2 |
2892 |
2892 |
tamoxifen |
| GSM232254 | GUYT2 |
LumB |
IBD |
PID |
ICR1 |
400003050 |
GUYT2_50377 |
DistantMetastasisFree |
7.3 |
DiseaseFree |
DistantMetastasisFree |
74 |
LN- |
ER+ |
PR+ |
G1 |
2.5 |
T2 |
2664 |
2664 |
tamoxifen |
| GSM232255 | GUYT2 |
LumA |
IBD |
PID |
ICR2 |
400003051 |
GUYT2_50378 |
DistantMetastasisFree |
6.08 |
DiseaseFree |
DistantMetastasisFree |
76 |
LN+ |
ER+ |
PR+ |
G1 |
1.69 |
T1c |
2221 |
2221 |
tamoxifen |
| GSM232256 | GUYT2 |
LumA |
IBD |
PID |
ICR1 |
400003052 |
GUYT2_50380 |
DistantMetastasisFree |
7 |
DiseaseFree |
DistantMetastasisFree |
55 |
LN+ |
ER+ |
PR+ |
G1 |
1.8 |
T1c |
2556 |
2556 |
tamoxifen |
| GSM232257 | GUYT2 |
LumA |
IBD |
PID |
ICR2 |
400003053 |
GUYT2_50382 |
DistantMetastasisFree |
8.08 |
DiseaseFree |
DistantMetastasisFree |
51 |
LN+ |
ER+ |
PR+ |
NA |
2.3 |
T2 |
2949 |
2949 |
tamoxifen |
| GSM232258 | GUYT2 |
LumB |
IBE |
FID |
ICR3 |
400003054 |
GUYT2_50383 |
DistantMetastasisFree |
7.08 |
DiseaseFree |
DistantMetastasisFree |
70 |
LN+ |
ER+ |
PR+ |
G2 |
1.8 |
T1c |
2584 |
2584 |
tamoxifen |
| GSM232259 | GUYT2 |
Her2 |
IBE |
FID |
ICR4 |
400003055 |
GUYT2_50384 |
DistantMetastasisFree |
2.84 |
DiseaseFree |
DistantMetastasisFree |
59 |
LN- |
ER+ |
PR- |
NA |
1.1 |
T1c |
1038 |
1038 |
tamoxifen |
| GSM232260 | GUYT2 |
Basal |
IBE |
FID |
ICR4 |
400003056 |
GUYT2_50385 |
DistantMetastasis |
2.41 |
Recurred/Progressed |
DistantMetastasis |
73 |
LN+ |
ER+ |
PR+ |
G3 |
1.5 |
T1c |
881 |
881 |
tamoxifen |
| GSM232261 | GUYT2 |
LumA |
IBD |
PID |
ICR1 |
400003057 |
GUYT2_50389 |
DistantMetastasisFree |
7.5 |
DiseaseFree |
DistantMetastasisFree |
71 |
LN+ |
ER+ |
PR+ |
G2 |
2.1 |
T2 |
2738 |
2738 |
tamoxifen |
| GSM232262 | GUYT2 |
LumB |
IBD |
FID |
ICR2 |
400003058 |
GUYT2_50391 |
DistantMetastasisFree |
6.36 |
DiseaseFree |
DistantMetastasisFree |
67 |
LN- |
ER+ |
PR+ |
NA |
2.55 |
T2 |
2321 |
2321 |
tamoxifen |
| GSM232263 | GUYT2 |
Her2 |
IBE |
PID |
ICR3 |
400003059 |
GUYT2_50395 |
DistantMetastasis |
2.9 |
Recurred/Progressed |
DistantMetastasis |
58 |
LN- |
ER+ |
PR- |
G3 |
2.7 |
T2 |
1059 |
1059 |
tamoxifen |
| GSM232264 | GUYT2 |
LumB |
IBE |
WID |
ICR2 |
400003060 |
GUYT2_50398 |
DistantMetastasisFree |
8.34 |
DiseaseFree |
DistantMetastasisFree |
72 |
LN+ |
ER+ |
PR+ |
G3 |
3.1 |
T2 |
3043 |
3043 |
tamoxifen |
| GSM232265 | GUYT2 |
Basal |
IBE |
PID |
ICR1 |
400003061 |
GUYT2_50400 |
DistantMetastasis |
5 |
Recurred/Progressed |
DistantMetastasis |
55 |
LN+ |
ER+ |
PR+ |
G2 |
4.5 |
T2 |
1825 |
1825 |
tamoxifen |
| GSM232266 | GUYT2 |
LumB |
IBE |
PID |
ICR2 |
400003062 |
GUYT2_50401 |
DistantMetastasisFree |
5.95 |
DiseaseFree |
DistantMetastasisFree |
52 |
LN- |
ER+ |
PR+ |
G2 |
1.8 |
T1c |
2170 |
2170 |
tamoxifen |
| GSM232267 | GUYT2 |
Her2 |
IBD |
FID |
ICR3 |
400003063 |
GUYT2_50402 |
DistantMetastasis |
5.28 |
Recurred/Progressed |
DistantMetastasis |
64 |
LN+ |
ER+ |
PR+ |
G2 |
2.5 |
T2 |
1629 |
1929 |
tamoxifen |
| GSM232268 | GUYT2 |
Basal |
IBE |
WID |
ICR3 |
400003064 |
GUYT2_50403 |
DistantMetastasisFree |
6.36 |
DiseaseFree |
DistantMetastasisFree |
68 |
LN+ |
ER+ |
PR+ |
NA |
1.85 |
T1c |
2322 |
2322 |
tamoxifen |
| GSM232269 | GUYT2 |
Basal |
IBE |
PID |
ICR1 |
400003065 |
GUYT2_50404 |
DistantMetastasisFree |
6.95 |
DiseaseFree |
DistantMetastasisFree |
63 |
LN- |
ER+ |
PR+ |
G2 |
2 |
T1c |
2538 |
2538 |
tamoxifen |
| GSM232270 | GUYT2 |
LumA |
IBD |
PID |
ICR2 |
400003066 |
GUYT2_50405 |
DistantMetastasisFree |
6.14 |
DiseaseFree |
DistantMetastasisFree |
71 |
LN- |
ER+ |
PR+ |
G1 |
1.1 |
T1c |
2240 |
2240 |
tamoxifen |
| Name | ||
|---|---|---|
| All Samples | Default | View |
| ER Status | View | |
| Histology Differentiation Grade | View | |
| Immune Benefit Status | View | |
| Immunological Constant of Rejection | View | |
| Lymph Node Status | View | |
| Molecular Subtype | View | |
| Pathology T Stage | View | |
| In order to make new Group Sets or change settings, please log in. | ||
| Group Set | |
|---|---|
| All Samples | |
| ER Status | |
| Histology Differentiation Grade | |
| Immune Benefit Status | |
| Immunological Constant of Rejection | |
| Lymph Node Status | |
| Molecular Subtype | |
| Pathology T Stage |